Local therapy for cutaneous and systemic lupus erythematosus: Practical and theoretical considerations

Lupus

Volumn 10, Issue 3, 2001, Pages 171-184

  Ting, W W ^a   Sontheimer, R D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Chronic cutaneous LE (discoid LE); Cutaneous LE; LE specific skin disease; Local therapy; Percutaneous penetration; Photosensitivity; Stratum corneum barrier; Subacute cutaneous LE; Sun protection; Sunscreens; Topical therapy; Uv protection

Indexed keywords

BETAMETHASONE DIPROPIONATE; CETAPHIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DIFLORASONE DIACETATE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; KERI SKIN; LANOLIN ALCOHOL; SUNSCREEN; ULOBETASOL PROPIONATE; VANICREAM;

ELECTROPORATION; HUMAN; IONTOPHORESIS; LOTION; PHOTOSENSITIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF CONCEPT; SKIN LUPUS ERYTHEMATOSUS; STRATUM CORNEUM; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035047042     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301667674688     Document Type: Review

References (84)

1. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
2. Sun exposure and the lupus patient
3. Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus
4. State of the art sunscreens for prevention of photodermatoses
5. Effect of daily versus intermittent sunscreen application on solar simulated UV radiation-induced skin response in humans
6. Modern approaches to photoprotection
7. Ultraviolet protection from sun avoidance
8. Fluorescent light photosensitivity in patients with systemic lupus erythematosus: Comment on the article by Rihner and McGrath
9. Burning questions about sunscreen
10. Photoprotection
11. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus
12. Recent advances in sun protection
13. An evaluation of broadspectrum sunscreens against topical PUVA-induced erythema
14. Efficiency of opaque photoprotective agents in the visible light range
15. Protective effects against sunburn of combined systemic ascorbic acid (vitamin C) and d-alphatocopherol (vitamin E)
16. Modulation of UV-light-induced skin inflammation by D-α-tocopherol and L-ascorbic acid: A clinical study using solar simulated radiation
17. Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage
18. Photoprotection of human skin by topical vitamin C
19. Vitamin C abrogates the deleterious effects of UVB radiation on cutaneous immunity by a mechanism that does not depend on TNF-α
20. Protection against long ultraviolet and/or visible light with topical dihydroxy acetone
21. Dihydroxyacetone for protection against long wavelength UVA radiation and blue light
22. Discovery and development of novel melanogenic drugs
23. Skin pigmentation and pharmacokinetics of melanotan-I in humans
24. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
25. Melanotropic peptides for therapeutic and cosmetic tanning of the skin
26. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin
27. In vitro transdermal delivery of a melanotropic peptide through human skin
28. Topical application of a melanotropic peptide induces systemic follicular melanogesis
29. DNA damage and melanogenesis
30. DNA damage enhances melanogenesis
31. DNA photodamage stimulates melanogenesis and other photoprotective responses
32. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
33. A role for NF-κB-dependent gene transactivation in sunburn
34. Genistein inhibits NF-κB activation in prostate cancer cells
35. Keratolytics and moisturizers. The practical guide to therapeutic drugs
36. Occlusive therapy of the ears in discoid lupus erythematosus
37. Oral insertable prosthetic device as an aid in treating oral ulcers
38. Clinical pearl - Discoid lupus erythematosus - Treatment with occlussive compression
39. Successful treatment of hypertrophic lupus erythematosus with isotretinoin
40. Effect of dimethylsulfoxide concentration on the permeability of neonatal rat stratum corneum to alkanols
41. Physiochemical study of percutaneous absorption enhancement by dimethyl sulfoxide: Dimethyl sulfoxide mediation of vidarabine (ara-A) permeation of hairless mouse skin
42. Some general influences of n-decylmethyl sulfoxide on the permeation of drugs across hairless mouse skin
43. Topical alpha-interferon ointment with dimethyl sulfoxide in the treatment of recurrent genital herpes simplex
44. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: Impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity
45. Recent trends in drug delivery systems: Liposomal drug delivery system-preparation and characterization
46. Liposomal tretinoin for uncomplicated acne vulgaris
47. Alcohols
48. Enhancements of percutaneous absorption of naproxen by phospholipids
49. Liposome-skin interactions and their effects on the skin permeation of drugs
50. A clinical evaluation of a novel liposomal carrier for acyclovir in the topical treatment of recurrent herpes labialis
51. Ethosomes - Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties
52. Direct current iontophoretic transdermal delivery of peptide and protein drugs
53. Physical enhancement of dermatologic drug delivery: Iontophoresis and phonophoresis
54. Iontophoretic delivery of model inorganic and drug ions
55. Effects of iontophoresis and electroporation on the stratum corneum. Review of the biophysical studies
56. Theory of electrical creation of aqueous pathways across skin transport barriers
57. Transdermal drug delivery using electroporation. I. Factors influencing in vitro delivery of terazosin hydrochloride in hairless rats
58. A mechanistic study of ultrasonically enhanced transdermal drug delivery
59. Defects generated in human stratum corneum specimens by ultrasound
60. Effect of low frequency ultrasound on the in vitro percutaneous absorption of Clobetasol 17-propionate
61. Effect of ultrasound application on skin metabolism of prednisolone 21-acetate
62. Laser ultrasonic transport of drugs in living tissues
63. Transdermal iontophoretic delivery of enoxacin from various liposome-encapsulated formulations
64. Cryogenic contact therapy of cutaneous lesions of lupus erythematosus
65. Discoid lupus erythematosus lesions treated with cryosurgery
66. Laser treatment of discoid lupus. (Case report)
67. Pulsed dye laser treatment in lupus erythematosus telangiectoides
68. Pulsed dye laser treatment of telangiectatic chronic erythema of cutaneous lupus erythematosus
69. Successful treatment of chronic discoid lupus erythematous with argon laser
70. Cutaneous lupus erythematosus-treatment with pulsed dye laser
71. Kobner phenomenon in lupus erythematosus
72. Dermabrasion from miscellaneous cutaneous scars (exclusive of scarring from acne)
73. Discoid lupus erythematosus treated by dermabrasion
74. Discoid lupus erythematosus scarring and dermabrasion: A case report and discussion
75. Connective tissue diseases
76. Treatment of lupus erythematosus by iontophoresis with plaquenil
77. Mechanism-oriented assessment of isotretinoin in chronic or subacute lupus erythematosus
78. Cutaneous lupus treated with topical tretinoin: A case report
79. Treatment of localized discoid lupus erythematosus with tazarotene
80. New and emerging therapies for collagen-vascular diseases
81. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases
82. FK506: Therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-1pr/1 pr mice
83. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus
84. Tacrolimus: The drug for the turn of the millennium?